Regorafenib Anhydrous
Regorafenib Anhydrous
Definition
The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.
Also known as 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide, BAY 73 4506, BAY 73-4506, BAY 734506, Regorafenib, REGORAFENIB ANHYDROUS — per NCIT
Also identified as
- ATC L01EX05 per RXNORM
- NCIT NCIT:C78204 per NCIT
- SCTID 702804006 per RXNORM
- SCTID 703808002 per RXNORM
- UNII 24T2A1DOYB per RXNORM
- UNII MGN125FS9D per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Colorectal neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |
| Gastrointestinal stromal tumor | may treat | MEDRT · Public domain (U.S. Government work) |
| Hepatocellular carcinoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Alimentary part of gastrointestinal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Liver | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.